Table 3.

Expression of new markers in paired samples of B-lineage ALL collected at diagnosis and at relapse

Marker	Patient 1		Patient 2		Patient 3		Patient 4		Patient 5		Patient 6		Patient 7		Patient 8		Patient 9
	D	R	D	R	D	R	D	R	D	R	D	R	D	R	D	R	D	R
CD44	—	—	233	235	372	—*	325	—*	—	—	—	—	3	4	208	93	292	307
BCL2	254	249	240	262	—	—	286	326	144	137	332	562	150	151	87	137	273	188
HSPB1	18	47	44	94	—	74†	169	143	141	165	64	351	23	267	15	158	80	36
CD73	30	39	37	64	56	149	29	105	—	—	95	30	33	—*	168	33	103	63
CD24	—	—	338	504	—	333†	204	146	104	2	—	277†	—	—	—	—	—	77†
CD123	—	—	62	31	—	—	45	133	—	—	—	—	—	—	—	—	—	25†
CD72	6	7	NT	NT	NT	NT	—	—	—	—	5	3	8	13	6	6	4	4
CD86	—	—	26	23	—	—	33	—*	—	—	—	—	—	—	—	—	—	—
CD200	86	65	107	88	—	—	80	201	260	154	—	—	102	126	—	72†	83	—*
CD164	—	—	18	49	—	—	—	—	—	—	—	—	—	29†	NT	NT	NT	NT
CD97	—	—	119	53	—	—	84	200	—	—	—	54†	—	—	—	—	—	—
CD102	—	—	—	—	—	—	96	92	—	—	—	—	—	100†	—	—	—	136†
CD99	—	—	—	—	—	—	—	329†	184	—*	124	—*	—	—	—	—	122	488

Values indicate MFI as determined by flow cytometry.

ALL indicates acute lymphoblastic leukemia; D, diagnosis; R, relapse; MFI, mean fluorescence intensity, NT, not tested; and —, MFI within the normal range.

^*Significant change in expression: from abnormal expression at diagnosis to expression within the normal range at relapse.

^†Significant change in expression: from expression within the normal range at diagnosis to abnormal expression at relapse.